← Leaderboards
Assem G Ziady
Cincinnati Childrens Hosp Med Ctr
$5,940,444
Attributed
$8,673,383
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2011–25$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,673,383 · 6
By mechanism
R01$7,127,136 · 3
R61$788,746 · 1
R21$437,250 · 1
R43$320,251 · 1
Top collaborators
- Zackary I Cleveland5 shared
- John Paul Clancy2 shared
- Rhonda Szczesniak2 shared
- Colin T. Sheehan1 shared
Most similar at Cincinnati Childrens Hosp Med Ctr
Same institution · by research overlap
- Zackary I Cleveland$6,645,866
- John Joseph Brewington$2,470,821
- Grant Sanford Schulert$3,706,690
- Elizabeth L Kramer$820,800
- Samuel Goldfarb$2,417,127
Others in their field
Top investigators on “Cystic Fibrosis Patients”
- Michael R Knowles · University Of North Carolina Chapel Hill$27,924,916
- Garry R Cutting · Johns Hopkins University$18,877,614
- John F Engelhardt · University Of Iowa$18,683,318
- John C Magee · University Of Michigan At Ann Arbor$18,424,429
- Robert M Merion · University Of Michigan At Ann Arbor$17,049,429
- Richard C Boucher · University Of North Carolina Chapel Hill$17,016,780
Research focus
Cystic Fibrosis PatientsCystic Fibrosis Transmembrane Conductance RegulatorLungCystic FibrosisPulmonary Cystic FibrosisClinical TrialsLung DiseasesBloodDisease ProgressionInflammationSeverity Of IllnessSuccessData AnalysesAdolescencePreventPathway InteractionsProteomicsBiological MarkersFutureCohortPredictive MarkerTranslatingBaseAffect
Grant awards (18)
Imaging and Molecular Phenotyping of Cystic Fibrosis Lung Disease$789,104
R01 · FY2025 · HL
Imaging and Molecular Phenotyping of Cystic Fibrosis Lung Disease$767,868
R01 · FY2024 · HL
A non-viral nanoparticle gene therapy delivery platform for treating Cystic Fibrosis and other diseases$320,251
R43 · FY2024 · HL
Imaging and Molecular Phenotyping of Cystic Fibrosis Lung Disease$783,539
R01 · FY2023 · HL
Imaging and Molecular Phenotyping of Cystic Fibrosis Lung Disease$789,560
R01 · FY2022 · HL
Predictive Molecular Markers of Lung Function Decline$441,754
R01 · FY2022 · HL · contact PI
Imaging and Molecular Phenotyping of Cystic Fibrosis Lung Disease$789,560
R01 · FY2021 · HL
Predictive Molecular Markers of Lung Function Decline$436,073
R01 · FY2021 · HL · contact PI
Commercial Translation of Biomarker-based Platform for Personalized Forecasting of Rapid Lung Function Decline$397,500
R61 · FY2021 · HL · contact PI
Predictive Molecular Markers of Lung Function Decline$436,073
R01 · FY2020 · HL · contact PI
Commercial Translation of Biomarker-based Platform for Personalized Forecasting of Rapid Lung Function Decline$391,246
R61 · FY2020 · HL · contact PI
Predictive Molecular Markers of Lung Function Decline$436,096
R01 · FY2019 · HL · contact PI
Targeting Vector Interactome to Enhance CFTR Delivery$198,750
R21 · FY2018 · EB · contact PI
Targeting Vector Interactome to Enhance CFTR Delivery$238,500
R21 · FY2017 · EB · contact PI
Dysregulation of Nrf2 in CF epithelia$358,729
R01 · FY2014 · HL · contact PI
Dysregulation of Nrf2 in CF epithelia$348,480
R01 · FY2013 · HL · contact PI
Dysregulation of Nrf2 in CF epithelia$357,800
R01 · FY2012 · HL · contact PI
Dysregulation of Nrf2 in CF epithelia$392,500
R01 · FY2011 · HL · contact PI